in this issue
Markets :: Fine Chemicals/Biotech :: Seeds and traits
Evogene raises $74 million in NYSE debut
9:37 AM MST | November 21, 2013 | Rebecca Coons
Shares of Evogene (Rehovot, Israel), a plant genomics firm in which both Monsanto and Bayer hold significant stakes, debuted on the New York Stock Exchange this morning at $14.75/share. The initial public offering raised approximately $74 million. Monsanto, which already held a 8.7% stake in Evogene, paid about $12 million to acquire 813,560 of the 5 million offered shares. Evogene says it has also granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same price per share. According to an F-1 filed in September...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee